MXPA02005649A - Nuevas combinaciones terapeuticas de (s)-2 -(bencilamino -metil)-2, 3, 8, 9-tetrahidro-7h -1, 4-dioxino(2-3 -e]indol-8 -ona y agentes neurolepticos para el tratamiento o prevencion de trastornos psicoticos. - Google Patents

Nuevas combinaciones terapeuticas de (s)-2 -(bencilamino -metil)-2, 3, 8, 9-tetrahidro-7h -1, 4-dioxino(2-3 -e]indol-8 -ona y agentes neurolepticos para el tratamiento o prevencion de trastornos psicoticos.

Info

Publication number
MXPA02005649A
MXPA02005649A MXPA02005649A MXPA02005649A MXPA02005649A MX PA02005649 A MXPA02005649 A MX PA02005649A MX PA02005649 A MXPA02005649 A MX PA02005649A MX PA02005649 A MXPA02005649 A MX PA02005649A MX PA02005649 A MXPA02005649 A MX PA02005649A
Authority
MX
Mexico
Prior art keywords
combinations
dioxino
neuroleptics
benzylamino
indol
Prior art date
Application number
MXPA02005649A
Other languages
English (en)
Inventor
Lovell Marquis Karen
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MXPA02005649A publication Critical patent/MXPA02005649A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La invencion se refiere a combinaciones farmaceuticas utiles en el tratamiento o prevencion de trastornos psicoticos, a composiciones farmaceuticas que las contienen, y a su uso en el tratamiento o profilaxis de trastornos psicoticos.
MXPA02005649A 1999-12-10 2000-12-07 Nuevas combinaciones terapeuticas de (s)-2 -(bencilamino -metil)-2, 3, 8, 9-tetrahidro-7h -1, 4-dioxino(2-3 -e]indol-8 -ona y agentes neurolepticos para el tratamiento o prevencion de trastornos psicoticos. MXPA02005649A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45860799A 1999-12-10 1999-12-10
PCT/US2000/033060 WO2001041750A2 (en) 1999-12-10 2000-12-07 Combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics

Publications (1)

Publication Number Publication Date
MXPA02005649A true MXPA02005649A (es) 2004-09-10

Family

ID=23821437

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02005649A MXPA02005649A (es) 1999-12-10 2000-12-07 Nuevas combinaciones terapeuticas de (s)-2 -(bencilamino -metil)-2, 3, 8, 9-tetrahidro-7h -1, 4-dioxino(2-3 -e]indol-8 -ona y agentes neurolepticos para el tratamiento o prevencion de trastornos psicoticos.

Country Status (20)

Country Link
EP (1) EP1235570A2 (es)
JP (1) JP5557409B2 (es)
KR (1) KR100772854B1 (es)
CN (1) CN1230164C (es)
AR (1) AR026756A1 (es)
AU (1) AU784211B2 (es)
BR (1) BR0016168A (es)
CA (1) CA2396351C (es)
CZ (1) CZ20021880A3 (es)
EA (1) EA005002B1 (es)
HK (1) HK1045942A1 (es)
HU (1) HUP0203309A3 (es)
IL (2) IL149669A0 (es)
MX (1) MXPA02005649A (es)
NO (1) NO20022739L (es)
NZ (1) NZ519381A (es)
PL (1) PL355292A1 (es)
TW (1) TWI222864B (es)
WO (1) WO2001041750A2 (es)
ZA (1) ZA200205484B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1874767A (zh) 2003-10-29 2006-12-06 惠氏公司 包含aplindore和其衍生物的缓释药物组合物
WO2006089053A2 (en) 2005-02-17 2006-08-24 Wyeth Cycloalkylfused indole, benzothiophene, benzofuran and indene derivatives
US20110059947A1 (en) * 2008-02-13 2011-03-10 Targacept, Inc. Alpha 7 nicotinic agonists and antipsychotics

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2987484B2 (ja) * 1995-03-16 1999-12-06 大塚製薬 株式会社 カルボスチリル誘導体の製造方法
US5756532A (en) * 1995-11-06 1998-05-26 American Home Products Corporation Aminomethyl-2 3 8 9-tetrahydro-7H-1 4-dioxino 2 3-E!-indol-8-ones and derivatives
GB9627005D0 (en) * 1996-12-27 1997-02-12 Knoll Ag Therapeutic agents

Also Published As

Publication number Publication date
CZ20021880A3 (cs) 2002-08-14
IL149669A (en) 2006-06-11
PL355292A1 (en) 2004-04-05
JP5557409B2 (ja) 2014-07-23
NO20022739D0 (no) 2002-06-07
EP1235570A2 (en) 2002-09-04
IL149669A0 (en) 2002-11-10
NZ519381A (en) 2004-04-30
ZA200205484B (en) 2003-12-31
AU784211B2 (en) 2006-02-23
CA2396351C (en) 2009-11-10
KR20030016207A (ko) 2003-02-26
WO2001041750A3 (en) 2002-02-14
EA200200656A1 (ru) 2002-12-26
CN1409633A (zh) 2003-04-09
TWI222864B (en) 2004-11-01
WO2001041750A2 (en) 2001-06-14
CA2396351A1 (en) 2001-06-14
HUP0203309A3 (en) 2004-12-28
CN1230164C (zh) 2005-12-07
HK1045942A1 (zh) 2002-12-20
AU1949001A (en) 2001-06-18
HUP0203309A2 (hu) 2003-01-28
NO20022739L (no) 2002-06-07
AR026756A1 (es) 2003-02-26
BR0016168A (pt) 2002-08-20
JP2003516350A (ja) 2003-05-13
KR100772854B1 (ko) 2007-11-02
EA005002B1 (ru) 2004-10-28

Similar Documents

Publication Publication Date Title
IL267381A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
TWI265808B (en) Valdecoxib compositions
EP1259240B8 (en) Agents, such as nicotinamide or cadpr for the treatment of skin disorders
AU6628496A (en) Polyether block copolymer micellar compositions for targeting biological agents
MY127980A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
IL152659A (en) Liquid pharmaceutical compositions comprising a pegylated human erythropoietin protein and a multiple charged inorganic anion, in a pharmaceutically acceptable buffer
HUP0104795A3 (en) Azabicycloalkanes as ccr5 modulators, pharmaceutical compositions comprising thereof and their use
AU2001266152A1 (en) Novel substituted nitrocatechols, their use in the treatment of some central andperipheral nervous system disorders and pharmaceutical compositions containing them
MXPA02004701A (es) Sales de hidroxieicosatetraenoato, composiciones y metodos de uso para tratar trastornos de resequedad en los ojos.
AU2300001A (en) Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease
IL140588A0 (en) Therapeutic composition based on flavonoids intended to be used in the treatment of tumours by cytotoxic agents
GR1003490B (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν αλας παροξετινης
SE0001916D0 (sv) Novel formulation
MXPA02005649A (es) Nuevas combinaciones terapeuticas de (s)-2 -(bencilamino -metil)-2, 3, 8, 9-tetrahidro-7h -1, 4-dioxino(2-3 -e]indol-8 -ona y agentes neurolepticos para el tratamiento o prevencion de trastornos psicoticos.
AP2000001946A0 (en) Form V1 5,6-Dichloro-2-(isopropylamino)-1-(B-L-Ribofuranosyl)-1H- benzimidazole.
BG104914A (en) Paroxetine maleate
JO2199B1 (en) Replaced pyrrols
WO2004006887A3 (en) Composition and methods for the treatment of skin disorders
TW374085B (en) Novel piperidine derivatives, their preparation, pharmaceutical formulation and medical use
AU3992897A (en) Use of sulbutiamine to obtain pharmaceutical compositions useful in the treatment of certain psychomotor and psycho-intellectual disorders
AU2002357691A1 (en) Methods and compositions to treat pain and painful disorders using 577, 20739 or 57145
TNSN00242A1 (en) VALDECOXIB COMPOSITIONS

Legal Events

Date Code Title Description
FG Grant or registration